GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Recombinant Factor VIIa, its Clinical
Properties, and the Tissue Factor
Pathway of Coagulation

[Does anyone have access to the full article? T.i.a.]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...

>>
Mini Rev Med Chem. 2006 Oct;6(10):1111-7.

Bosinski TJ, El Solh AA.

Division of Pulmonary, Critical Care, and Sleep Medicine, Erie County Medical Center, 462 Grider Street, Buffalo, NY 14215, USA.

Recombinant factor VIIa (rFVIIa) is a synthetic coagulation protease that is structurally similar to human-derived plasma FVIIa. Pharmacologic doses of rFVIIa have been shown to enhance thrombin generation and assist in forming stable fibrin plugs at the site of injury. Recombinant factor VIIa appears to emerge as a valuable treatment alternative for the treatment of bleeding episodes and for achieving hemostasis post surgery in those with bleeding disorders.
<<